In­cyte yanks EU ap­pli­ca­tion for PD-1 drug, cit­ing in­abil­i­ty to an­swer reg­u­la­tors' 'ma­jor con­cern­s'

Hop­ing to wedge its way in­to a crowd­ed PD-(L)1 field, In­cyte faced a huge set­back when the FDA sent back its ap­pli­ca­tion for an ini­tial in­di­ca­tion ear­li­er this year. Now, the drug­mak­er is giv­ing up hope in Eu­rope as well.

In­cyte has with­drawn its EU ap­pli­ca­tion for PD-1 drug Zynyz, or reti­fan­limab, af­ter say­ing it couldn’t ad­e­quate­ly ad­dress the CHMP’s ques­tions over sur­vival da­ta un­der­pin­ning its mar­ket hopes in squa­mous cell car­ci­no­ma of the anal cav­i­ty, the EMA re­vealed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER